Summary Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also a growth-promoting function. However, the significance of the expression of TIMP-1 in human gastric carcinoma tissue has yet to be clarified.
multivariate analysis
Tumour cells have to degrade the components of the extracellular matrix (ECM) to invade the surrounding tissue and the vascular or lymphatic vessels to form metastatic colonies at distant sites. The matrix degradation in the basement membrane during the metastatic process is, more or less, closely related to activities of various subtypes of matrix metalloproteinase (MMP) and the corresponding tissue inhibitor of matrix metalloproteinase (TIMP) . In general, MMPs facilitate the invasion of the tumour; on the other hand, TIMPs also play an important role in inhibiting MMPs. The TIMP-1 transfected cells or carcinoma cells with an abundant expression of TIMP-1 mRNA inhibit the MMPs' activity to invade the model of basement membranes in various human carcinoma cell lines (Sato et al, 1992; Azuma et al, 1993; Tsuchiya et al, 1993; Belloc et al, 1995; Miyagi et al, 1995) .
Recent studies have reported an alternative function of TIMP-1, i.e. as a growth factor; it is highly homologous with erythroid potentiating activity (EPA), which is an autocrine growth factor for the erythroid leukaemia cell line K562 (Docherty et al, 1985 ; Avalos et al, 1988) . Moreover, TIMP-1 also shares homology with a fibroblast elongation factor that is secreted from colon carcinoma cells and which stimulates tumour cell proliferation (Agrez et al, 1995) . The TIMP-1 RNA levels were higher in primary colorectal carcinomas with distant metastasis than in those without metastasis (Zeng et al, 1995) , and the expression of TIMPs increased with the advance of the neoplastic process (Urbanski et al, 1993) . With respect to gastric carcinoma, the enhanced TIMP-1 production in carcinoma tissues was also reported by Nomura et al (1996) In the present study, we studied the expression of TIMP-1 mRNA in human gastric carcinoma tissue by an RT-PCR assay that enabled us to analyse small sample amounts, such as biopsy specimens, before surgery (Hirokoshi et al, 1992) . We examined the correlation between its expression and clinicopathological variables, as well as the significance of its expression as an independent factor to predict the depth of tumour invasion and patient prognosis. We would thus like to emphasize that TIMP-1 expression may be one of the factors indicating the aggressiveness of gastric carcinomas.
MATERIALS AND METHODS Biopsy specimens
Biopsy specimens from 50 patients, including 30 men and 20 women, with gastric carcinoma were available for this study. The average age was 67.5 years with a range from 38 to 87 years. We obtained three and four biopsy specimens from the tumour and normal tissue respectively. Two specimens from tumour tissue and two specimens from normal tissue were used for RNA extraction. The other specimens from the tumour and normal tissue were used for the pathological diagnosis. For tumour biopsy samples, we obtained the tissue from the edge of the primary tumour because the edge area contains both tumour and stromal tissues in the specimen. Consequently, we checked and confirmed that all biopsy specimens stained with haematoxylin and eosin contained tumour epithelial tissue and stromal tissue in the tumour biopsy specimen, and normal epithelial tissue and stromal tissue in the normal biopsy specimen. In most of the above cases, normal biopsy specimens, i.e. specimens obtained from the non-cancerous mucosal tissue, disclosed chronic gastritis with mild to severe stromal fibrosis and inflammatory cell infiltration. RNA preparation from tissue specimens
The samples for RNA extraction were immediately stored at -80°C until use. The total RNA was then extracted according to the method of acid guanidinium thiocyanate -phenol -chloroform extraction (Chomczynski and Sacchi, 1987) . All samples were treated in Eppendorf tubes (Eppendorf, Germany) and were handled with gloves to avoid contamination with RNAase.
Reverse transcription
The total RNA of both the tumour and the normal samples from the 50 cases was then reverse transcribed using random hexamer primers into the cDNA as described previously (Mori et al, 1995) .
Oligonucleotide primers of TIMP-1
On the GenBank accession no. S68252, both the sense and antisense primers were synthesized using by an Applied Biosynthesis 394 PCR-Mate DNA Synthesizer. The primer sequences of TIMP-1 were as follows: sense primer (5'-GCCCCTGGCTTCTG-GCATCCT-3') corresponding to human TIMP cDNA 18 to 38 (GenBank) and antisense (5'-GAGGCAGGCAGGCAAGGTGAC-3') corresponding to human TIMP cDNA 557 to 577 (GenBank). These primers amplified the 559-bp fragment of TIMP-1 cDNA.
The semiquantitative detection of mRNA
In order to evaluate the amplified product quantitatively by PCR, preliminary experiments were carried out to determine the suitable number of cycles using the linear range of the PCR product in cDNA from MKN-7, a representative gastric carcinoma cell line ( Figure 1 ) (Wang et al, 1989 
RESULTS

Reproducibility of RT-PCR analysis
The first and the second results were almost the same in each case and showed a good reproducibility (Figure 2 ).
Comparison of the data from the resected specimens and the biopsy specimens
The T/N ratio of TIMP-1 expression in the resected specimens was 3.84, while that in the biopsy specimens was 3.55. There was a good correlation between the two as shown in Figure 3 (r = 0.734, P = 0.016). These findings suggest that the results of the biopsy specimens reflect those of the resected specimens.
Analysing the TIMP-1 mRNA levels in tumour and normal tissues
The expression of TIMP-1 mRNA in all 50 cases with gastric carcinoma was observed in both the tumour and the normal samples (Figure 4 ). Twenty patients belonging to stage III or IV showed a significantly higher T/N ratio of TIMP-1 mRNA than the 30 patients belonging to stage I or II (P = 0.042). A significant difference was also observed between the T/N ratio in the 12 patients who died of primary cancer and that of the 36 patients who were still alive at the time of writing (P = 0.007). With respect to the depth of tumour invasion, the cases of tumours invading the subserosa or deeper showed a higher T/N ratio than those invading up to the muscularis propria, but it did not reach a statistically significant difference (P = 0.077). No significant differences were found between any other clinicopathological features.
The logistic analysis is shown in Table 2 . TIMP-1 was the third, and independent, determinant factor for the depth of tumour invasion (r = 1.748, P = 0.038) (Table 2A) . Although TIMP-1 was not an independent prognostic factor (r = 0.080, P = 0.07), it was the second major prognostic factor after the depth of tumour invasion (Table 2B) .
DISCUSSION
Three TIMP genes (TIMP-1, TIMP-2 and TIMP-3) have so far been identified (Murphy et al, 1981; Stettler-Stevenson et al, 1989; Palvoff et al, 1992) . TIMP-1 possesses 41% amino acid homology with TIMP-2. TIMP-1 is a Mr 28 000 glycoprotein and binds to MMPs in a 1:1 molar ratio and specifically inhibits MMP activities (Welgus et al, 1981) . TIMP-1 forms a complex with proMMP9 and inhibits the activation of proMMP9 by stromelysin (Goldberg et al, 1992) ; inhibition of activity is the result of binding the active site of the MMP (Birkedal-Hansen et al, 1993; Denhardt et al, 1993) .
During the invasion and metastatic progression of the carcinoma cells, TIMPs have been reported to be a negative regulator of MMPs in human and mouse tumour models in vitro and in vivo. The TIMP-l antisense transfected Swiss 3T3 cell lines reduced the invasive activity with a lower expression of TIMP-1 (Khokha et al, 1989) . TIMP-1 gene transfected gastric carcinoma cells have been reported to reduce the ability of invasion or metastasis (Tsuchiya et al, 1993) . Several previous studies have revealed that highly malignant tumours produce both higher MMPs and lower TIMPs, while less malignant tumours successfully inhibit the activities of MMPs by TIMP activity (Sato et al, 1992; Azuma et al, 1993; Miyagi et al, 1995; Mohanam et al, 1995) .
However, in another study using clinical samples, the expression of TIMP mRNA was higher in carcinoma tissue. In studies of various carcinoma cases, such as stomach, colorectal, head and neck, and pancreas, both MMPs and TIMPs were found to correlate with an increased metastatic and invasive potential of tumour cells (Polette et al, 1993; Urbanski et al, 1993; Gress et al, 1995; Zeng et al, 1995; Nomura et al, 1996) . Zeng et al (1995) reported that higher TIMP-1 RNA levels were found in colorectal carcinoma with metastasis than in those without metastasis. Urbanski et al (1993) reported that the expression of TIMP mRNA thus paralleled the expression of MMPs and was also highly intercorrelated with the neoplastic process of human sporadic colorectal carcinomas. We demonstrated in this gastric carcinoma study that the expression of TIMP-1 RNA was an independent factor influencing (Campbell et al, 1991; Lotz and Guerne, 1991; Partridge et al, 1993; Richards and Agro, 1994) . Second, as suggested by several investigators, TIMP-1 has two distinct activities, i.e. a metalloproteinase inhibitory activity and a growth factor activity (Avalos et al, 1988; Agrez et al, 1995; Chesler et al, 1995) .
Recent advances in the techniques of molecular biology have enabled clinicians to obtain both more detailed and more objective information on tumour biology. Such advances include the clarification of multiple-step carcinogenesis in gastrointestinal carcinomas; molecular-level diagnoses, such as the detection of micrometastasis in lymph nodes (Mori et al, 1995) , bone marrow or peripheral blood samples (Mori et al, 1996) ; or molecular-level new therapies, such as gene therapy. A new, molecular-level prognostic factor still needs to be established that can be widely used in the practical follow-up of patients (Mori et al, 1993a and b) . RT-PCR assays enable the molecular biological analysis of small samples. Some problems exist, however, when performing such analyses on small biopsy samples. The first is the problem of reproducibility. In this study, we confirmed that RT-PCR for the TIMP-1 gene showed almost the same results when the experiments were repeated. The second problem is whether or not the biopsy specimens accurately reflect the whole material of the resected specimens. We compared the RT-PCR results obtained from biopsy specimens with those from resected specimens. The results consequently demonstrated a significantly good correlation. We thus consider that, at least for the TIMP-1 gene, the results obtained from the biopsy specimens accurately reflect those obtained from resected specimens of the primary tumour, and we believe that useful preoperative information on molecular-level factors can be achieved by the molecular examination of biopsy specimens.
The present study demonstrated that the evaluation of TIMP-1 expression using an RT-PCR assay with biopsy specimens may therefore be useful in predicting the aggressive behaviour of gastric carcinomas. Such an assay is objective and can be done preoperatively, and therefore it is considered to be useful in a clinical setting.
